سعر جالفس ميت 50/850مجم 30 قرص 2024

Galvus Met 50/850 mg film-coated tablets (Novartis): vildagliptin 50 mg + metformin hydrochloride 850 mg per tablet, a DPP-4 inhibitor/biguanide combination for type 2 diabetes; pack of 30 tablets (3 x 10).

• Type 2 diabetes inadequately controlled on maximal tolerated dose of metformin alone (adjunct to diet and exercise)Population: Adults with type 2 diabetes mellitusEuropean Medicines Agency (EMA)
• Type 2 diabetes in patients already treated with vildagliptin and metformin as separate tabletsPopulation: Adults with type 2 diabetes mellitusEuropean Medicines Agency (EMA)
• Type 2 diabetes in combination with other antidiabetic medicines, including insulin, when these and metformin do not give adequate controlPopulation: Adults with type 2 diabetes mellitusEuropean Medicines Agency (EMA)

• Common: dizziness, headache, tremor, nausea, vomiting, diarrhoea, abdominal pain and hyperhidrosis; metformin commonly causes gastrointestinal effects and can lower vitamin B12 levels. Uncommon/rare: pancreatitis, hepatitis, lactic acidosis.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or excipients; any acute metabolic acidosis (lactic acidosis, diabetic ketoacidosis); diabetic pre-coma; severe renal failure (GFR < 30 mL/min); acute conditions that may alter renal function (dehydration, severe infection, shock, intravascular iodinated contrast); conditions causing tissue hypoxia (heart or respiratory failure, recent MI, shock); hepatic impairment; acute alcohol intoxication, alcoholism; breastfeeding.International label, same formulation · European Medicines Agency (EMA)

• Lactic acidosis (rare, serious): risk rises with renal impairment, dehydration, alcohol, hepatic impairment and hypoxia; stop and seek care if suspected.International label, same formulation · European Medicines Agency (EMA)
• Stop before or at the time of iodinated contrast imaging or surgery under general, spinal or epidural anaesthesia; restart no sooner than 48 hours afterwards once renal function is stable.International label, same formulation · European Medicines Agency (EMA)
• Rare hepatic dysfunction (including hepatitis) with vildagliptin: test liver function before treatment, every 3 months in the first year and periodically thereafter; stop if ALT/AST persistently > 3 x ULN or jaundice occurs.International label, same formulation · European Medicines Agency (EMA)

• Iodinated contrast agentsStop before or at the time of the imaging procedure; restart no sooner than 48 hours after, once renal function is stable (risk of lactic acidosis).European Medicines Agency (EMA)
• AlcoholAlcohol intoxication increases the risk of lactic acidosis; avoid alcohol and alcohol-containing medicines.European Medicines Agency (EMA)
• ACE inhibitorsPossible increased risk of angioedema with vildagliptin.European Medicines Agency (EMA)

• Should not be used during pregnancy (insufficient human data for vildagliptin).International label, same formulation · European Medicines Agency (EMA)
• Contraindicated during breastfeeding.International label, same formulation · European Medicines Agency (EMA)

• Vildagliptin: Inhibits DPP-4, raising active GLP-1 and GIP levels and improving glucose-dependent insulin secretion and glucagon suppression (EU SmPC).
• Metformin hydrochloride: Lowers basal and postprandial glucose by reducing hepatic glucose production, increasing peripheral glucose uptake and delaying intestinal glucose absorption (EU SmPC).